Intellectual Property News & Topics - Secerna LLP

VENCLEXTA®

A to Z: Drugs in Highlight: V is for VENCLEXTA®

News A to Z Feature 30/04/2025

Our A to Z series highlights VENCLEXTA® (venetoclax) from AbbVie, a medication used to treat both chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This article explores its mechanism of action, clinical applications, and the patent protection surrounding this important drug.

Read more

Ozempic (1)

News, A to Z Feature 13/03/2025

A to Z: Drugs in Highlight: O is for OZEMPIC®

Patent Box Update 2025 (2)

Industry news, News 10/03/2025

Unlocking Innovation: The Latest on the UK Patent Box Scheme

NILEMDO

News, A to Z Feature 07/03/2025

A to Z: Drugs in Highlight: N is for NILEMDO®

Nepic Jason And Melvyn

Events, Team news 06/03/2025

Secerna attending NEPIC Cluster Connect 2025

Jason And Jacob

Industry news, News, Team news 04/03/2025

Secerna Expands Physics Team with New Trainee Patent Attorney

Sam

News, Team news, Careers 04/03/2025

Learn about life as a Trade Mark Attorney

M is for MAVIRET

News, A to Z Feature 28/02/2025

A to Z: Drugs in Highlight: M is for MAVIRET®

Secerna Interior Shots September 2024 022 (1)

News, Careers 25/02/2025

Explore a Career in IP: Secerna Taster Day

LEQEMBI

News, A to Z Feature 19/02/2025

A to Z: Drugs in Highlight: L is for LEQEMBI®

1 2 3 4 5 6 7 8